Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Esaxerenone 5 mg Tablet vs Esaxerenone 5 mg Orally Disintegrating Tablet
jRCT1080224760Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of esaxerenone in hypertension (HTN) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Cmax bioequivalence and AUClast bioequivalence. Started Jul 2019; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT1080224760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224760.